40 results on '"Dessinioti, Clio"'
Search Results
2. Acne
- Author
-
Dessinioti, Clio, Dreno, Brigitte, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
3. New Drug Developments in Acne
- Author
-
Gollnick, Harald P. M., Dessinioti, Clio, Zouboulis, Christos C., Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, and Suh, Dae Hun, editor
- Published
- 2021
- Full Text
- View/download PDF
4. Hidradenitis Suppurativa
- Author
-
Dessinioti, Clio, Zouboulis, Christos, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
5. Recent Advances in the Diagnosis and Management of High-Risk Cutaneous Squamous Cell Carcinoma.
- Author
-
Dessinioti, Clio and Stratigos, Alexander J.
- Subjects
- *
DISEASE progression , *CANCER relapse , *SKIN tumors , *RISK assessment , *RADIOTHERAPY , *SQUAMOUS cell carcinoma , *DIFFUSION of innovations , *CANCER patient medical care , *DISEASE risk factors ,RISK of metastasis - Abstract
Simple Summary: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although most cSCCs are effectively treated with surgery, there are some tumors at higher risk for relapse, progression to nodal metastasis, or, rarely, death. An important issue concerns the early diagnosis and appropriate treatment of these few high-risk cSCCs, as they are associated with poorer prognosis and may more frequently progress to advanced cSCCs. This review discusses the characteristics of high-risk cSCC and how to identify and manage patients with these tumors. High-risk cSCC is defined as invasive cSCC staged as N0 (without detectable regional lymph nodes) and M0 (without distant metastasis), that has features associated with a higher risk of poorer prognosis. The focus of this review is on the recent advances in the diagnosis and management of high-risk cSCC. The interest in high-risk cSCC relies on its higher risk of progression to advanced cSCC, as it represents the main pool of cSCCs that give rise to advanced tumors. Assessment of the risk is thus particularly relevant for common cSCC to identify the few with a high-risk risk of local recurrence, metastasis, or disease-specific death among all other low-risk tumors. The timely diagnosis and effective treatment of high-risk cSCCs may halt their further progression and aim to prevent and lower the incidence of advanced cSCCs. Clearance of the tumor with negative surgical margins is the main goal of surgery, which is the primary treatment of cSCC. It seems that it is difficult to discern the group of high-risk cSCCs that may benefit from adjuvant RT, as a universal beneficial effect for a cSCC with any high-risk factor which was resected with clear surgical margins has not been established. In the case of a high-risk cSCC with positive margins after surgery, and re-excision not feasible, post-operative radiotherapy is performed when possible. Recommendations on further management are discussed. Regarding the follow-up of patients diagnosed with high-risk cSCC, factors to consider regarding the frequency and intensity of the follow-up schedule include the risk and possible time of occurrence of metastasis from cSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
- Author
-
Stratigos, Alexander J, Garbe, Claus, Dessinioti, Clio, Lebbe, Celeste, Bataille, Veronique, Bastholt, Lars, Dreno, Brigitte, Concetta Fargnoli, Maria, Forsea, Ana M, Frenard, Cecille, Harwood, Catherine A, Hauschild, Axel, Hoeller, Christoph, Kandolf-Sekulovic, Lidija, Kaufmann, Roland, Kelleners-Smeets, Nicole W J, Malvehy, Josep, Del Marmol, Veronique, Middleton, Mark R, Moreno-Ramirez, David, Pellecani, Giovanni, Peris, Ketty, Saiag, Philippe, van den Beuken-van Everdingen, Marieke H J, Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M M, Grob, Jean-Jacques, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), HAL UVSQ, Équipe, National and Kapodistrian University of Athens (NKUA), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), North & East Hertfordshire NHS Trust [Northwood, UK], Odense University Hospital (OUH), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), University of L'Aquila [Italy] (UNIVAQ), University of Bucharest (UniBuc), Queen Mary University of London (QMUL), Kiel University, Medizinische Universität Wien = Medical University of Vienna, Military Medical Academy [Belgrade, Serbia] (2MA), Frankfurt University Hospital, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Enfermedades Raras (CIBERER), Université libre de Bruxelles (ULB), University of Oxford, Hospital Universitario Virgen Macarena [Sevilla, Spain] (HUVM), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Coimbra Hospital and Universitary Centre [Coimbra, Portugal] (CHUC), Università degli studi di Trieste = University of Trieste, Princess Máxima Center for Pediatric Oncology, Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Amgen Bristol-Myers Squibb, BMS Pfizer AstraZeneca GlaxoSmithKline, GSK Merck Novartis Roche Sanofi AbbVie Meso Scale Diagnostics, MSD Merck Sharp and Dohme, MSD DUSA Pharmaceuticals Les Laboratories Pierre Fabre Cilag LEO Pharma Research Foundation, The development of the current set of guideline was supported solely by funds of the EADO which were used to mainly support the consensus meeting.Dr. Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, AbbVie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Garbe reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from NeraCare, grants and personal fees from BMS, personal fees from Pierre Fabre, personal fees from Philogen, grants and personal fees from Roche, grants and personal fees from Sanofi, outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche, personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis, personal fees from Merck MSD, outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS, Roche, Novartis, Pierre Fabre, AstraZeneca, Incyte, MSD/Merck, Bayer. Dr. Dr?no reports grants and personal fees from BMS, personal fees from MSD, grants and personal fees from Roche, grants and personal fees from Fabre, grants and personal fees from Sanofi, outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall, grants and personal fees from Leo Pharma, personal fees from Janssen, grants and personal fees from Novartis, personal fees from Lilly, grants and personal fees from Sanofi, personal fees from UCB, grants and personal fees from AbbVie, personal fees from Celgene, personal fees from Pierre Fabre, grants and personal fees from Galderma, personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche, personal fees from Sun Pharma, outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis, Leo Pharma, Solartium, Pierre Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi, Novartis, Merck, Pfizer, Galderma, Meda, Almirall, PellePharm, Leo Pharma, Ceries. Dr. Hauschild reports honoraria and/or research grants from Almirall, BMS, Roche, Novartis, Pierre Fabre, Sun Pharma, Merck Serono, Sanofi-Aventis, Regeneron, MSD/Merck, Philogen, OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen, personal fees from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers? honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from AbbVie, Amgen, Biontech, BMS, Celgene, Galderma, Janssen, Leo, Lilly, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Regeneron, Roche, Wyeth. Advisory board and honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development, other from Janssen-Cilag, other from AbbVie, other from Galderma, outside the submitted work. Dr. Malvehy reports research grants from Almirall, ISDIN, Leo Pharma, Galderma, GSK, Cantabria, participation in advisory board meetings for Almirall, Sun Pharma, BMS, Roche, Novartis, Pierre Fabre. Dr. del Marmol reports personal fees from MSD, from BMS, personal fees from Sanofi, grants and personal fees from AbbVie, grants from Janssen, outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen, Roche, AstraZeneca, GSK, Novartis, Immunocore, BMS, Eisai and Merck. Institutional funding from Millennium, Vertex, Pfizer, Regeneron, TC Biopharm, BioLineRx, Replimune, outside the submitted work. Dr. Moreno-Ram?rez has nothing to disclose. Dr. Pellecani reports grants from university of Modena and Reggio Emilia, during the conduct of the study, grants from Novartis, grants and personal fees from Almirall, grants from Leo Pharma, from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie, Almirall, Biogen Celgene, Lilly, Galderma, Leo Pharma, Novartis, Roche, Sanofi, Sun Pharma, Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen, Bristol-Myers Squibb, MSD, Merck Serono, Novartis, Pfizer, Roche-Genentech, Pierre Fabre, and Sanofi, outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi, Sun Pharma, Novartis, Galderma, Roche, Celgene, Almirall, Leo Pharma, Mylan, Difa Cooper, Cieffe Labs, La Roche Posay, Pierre Fabre. Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for BIOCAD, BioInvent, Bristol-Myers Squibb (BMS), CatalYm, Ellipses, GlaxoSmithKline (GSK), HalioDx, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme (MSD), Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SELLAS, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen, Roche, GSK, Novartis, BMS, Pierre Fabre, Merck, Sanofi, Merck, Pfizer outside the submitted work., Dr. Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, AbbVie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Garbe reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis , grants and personal fees from NeraCare , grants and personal fees from BMS , personal fees from Pierre Fabre, personal fees from Philogen, grants and personal fees from Roche , grants and personal fees from Sanofi , outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb , personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche , personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis, personal fees from Merck MSD, outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS, Roche, Novartis, Pierre Fabre, AstraZeneca, Incyte, MSD/Merck, Bayer. Dr. Dréno reports grants and personal fees from BMS , personal fees from MSD, grants and personal fees from Roche , grants and personal fees from Fabre , grants and personal fees from Sanofi , outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall , grants and personal fees from Leo Pharma , personal fees from Janssen, grants and personal fees from Novartis , personal fees from Lilly, grants and personal fees from Sanofi , personal fees from UCB, grants and personal fees from AbbVie , personal fees from Celgene, personal fees from Pierre Fabre, grants and personal fees from Galderma , personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche, personal fees from Sun Pharma, outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis, Leo Pharma, Solartium, Pierre Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi , Novartis , Merck , Pfizer , Galderma , Meda , Almirall , PellePharm , Leo Pharma , Ceries . Dr. Hauschild reports honoraria and/or research grants from Almirall , BMS , Roche , Novartis , Pierre Fabre , Sun Pharma , Merck Serono , Sanofi-Aventis , Regeneron , MSD/Merck , Philogen , OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen , personal fees from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers’ honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from AbbVie , Amgen , Biontech , BMS , Celgene , Galderma , Janssen , Leo , Lilly , Merck , MSD , Novartis , Pierre Fabre , Pfizer , Regeneron , Roche , Wyeth . Advisory board and honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development , other from Janssen-Cilag, other from AbbVie, other from Galderma, outside the submitted work. Dr. Malvehy reports research grants from Almirall , ISDIN , Leo Pharma , Galderma , GSK , Cantabria, participation in advisory board meetings for Almirall, Sun Pharma, BMS, Roche, Novartis, Pierre Fabre. Dr. del Marmol reports personal fees from MSD, from BMS, personal fees from Sanofi, grants and personal fees from AbbVie, grants from Janssen , outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen , Roche , AstraZeneca , GSK , Novartis , Immunocore , BMS , Eisai and Merck . Institutional funding from Millennium , Vertex , Pfizer , Regeneron , TC Biopharm , BioLineRx , Replimune , outside the submitted work. Dr. Moreno-Ramírez has nothing to disclose. Dr. Pellecani reports grants from university of Modena and Reggio Emilia , during the conduct of the study, grants from Novartis , grants and personal fees from Almirall , grants from Leo Pharma , from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie , Almirall , Biogen Celgene , Lilly , Galderma , Leo Pharma , Novartis , Roche , Sanofi , Sun Pharma , Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen , Bristol-Myers Squibb , MSD , Merck Serono , Novartis , Pfizer , Roche-Genentech , Pierre Fabre , and Sanofi , outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi , Sun Pharma , Novartis , Galderma , Roche , Celgene , Almirall , Leo Pharma , Mylan , Difa Cooper , Cieffe Labs , La Roche Posay , Pierre Fabre . Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for BIOCAD, BioInvent, Bristol-Myers Squibb (BMS), CatalYm, Ellipses, GlaxoSmithKline (GSK), HalioDx, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme (MSD), Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SELLAS, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen, Roche, GSK, Novartis, BMS, Pierre Fabre, Merck, Sanofi, Merck, Pfizer outside the submitted work., European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), Stratigos, A. J., Garbe, C., Dessinioti, C., Lebbe, C., Bataille, V., Bastholt, L., Dreno, B., Concetta Fargnoli, M., Forsea, A. M., Frenard, C., Harwood, C. A., Hauschild, A., Hoeller, C., Kandolf-Sekulovic, L., Kaufmann, R., Kelleners-Smeets, N. W. J., Malvehy, J., del Marmol, V., Middleton, M. R., Moreno-Ramirez, D., Pellecani, G., Peris, K., Saiag, P., van den Beuken-van Everdingen, M. H. J., Vieira, R., Zalaudek, I., Eggermont, A. M. M., Grob, J. -J., Dermatologie, MUMC+: MA Dermatologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, RS: MHeNs - R3 - Neuroscience, Anesthesiologie, MUMC+: MA Anesthesiologie (9), and MUMC+: TPZ Palliatieve Zorg (9)
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,Skin Neoplasms ,medicine.medical_treatment ,Dermatologic Surgical Procedures ,Aftercare ,Anti-PD-1 antibody ,Cemiplimab ,Chemotherapy ,Cutaneous squamous cell carcinoma ,EGFR inhibitors ,Follow-up ,Locally advanced ,Metastatic ,Radiotherapy ,Surgical excision ,Treatment ,Medical Oncology ,Metastasis ,METASTATIC CUTANEOUS HEAD ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Quality of life ,IN-TRANSIT METASTASIS ,Monoclonal ,ADJUVANT RADIOTHERAPY ,Lymph node ,Humanized ,Societies, Medical ,Skin ,Cetuximab ,Palliative Care ,Margins of Excision ,Chemoradiotherapy ,3. Good health ,EGFR inhibitor ,Dissection ,medicine.anatomical_structure ,Immunological ,030220 oncology & carcinogenesis ,PHASE-II ,Carcinoma, Squamous Cell ,Sunlight ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,medicine.drug ,medicine.medical_specialty ,Consensus ,Clinical Decision-Making ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Antineoplastic Agents ,CERVICAL LYMPH-NODES ,Dermatology ,Antibodies, Monoclonal, Humanized ,ELECTIVE NECK DISSECTION ,Antibodies ,03 medical and health sciences ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Patient Education as Topic ,Internal medicine ,Humans ,Lymph Node Excision ,Lymph Nodes ,Neoplasm Staging ,Patient Care Team ,Medical ,medicine ,ORGAN TRANSPLANT RECIPIENTS ,business.industry ,Carcinoma ,Guideline ,medicine.disease ,Cancérologie ,Radiation therapy ,030104 developmental biology ,Squamous Cell ,INTERFERON-ALPHA ,business ,GROWTH-FACTOR RECEPTOR ,Societies ,INTRALESIONAL METHOTREXATE - Abstract
In order to update recommendations on treatment, supportive care, education and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer was formed. Recommendations were based on evidence-based literature review, guidelines and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable) and distant metastatic cSCC. For common primary cSCC (the most frequent cSCC type), first-line treatment is surgical excision with postoperative margin assessment or microscopically controlled sugery. Safety margins containing clinical normal-appearing tissue around the tumour during surgical excision and negative margins as reported in the pathology report are necessary to minimise the risk of local recurrence and metastasis. In case of positive margins, a re-excision shall be done, for operable cases. Lymph node dissection is recommended for cSCC with cytologically or histologically confirmed regional nodal involvement. Radiotherapy should be considered as curative treatment for inoperable cSCC, or for non-surgical candidates. Anti-PD-1 antibodies are the first-line systemic treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drug Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiation therapy. Multidisciplinary board decisions are mandatory for all patients with advanced disease who require more than surgery. Patients should be engaged with informed decisions on management and be provided with best supportive care to optimise symptom management and improve quality of life. Frequency of follow-up visits and investigations for subsequent new cSCC depend on underlying risk characteristics., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2020
- Full Text
- View/download PDF
7. Beta-Blockers for Hemangiomas
- Author
-
Gelmetti, Carlo, Cavalli, Riccardo, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
8. Antiviral Drugs in Dermatology and Venereology
- Author
-
Skerlev, Mihael, Čulav, Ivana, Stanimirović, Andrija, Kutlić, Dominik, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
9. Psychotherapeutic and Psychiatric Approach in Dermatovenereology
- Author
-
Vojvodic, Petar, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
10. Syphilis
- Author
-
Waugh, Michael, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
11. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
- Author
-
Melikoğlu, Mehmet, Pala, Erdal, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
12. Sweet Syndrome
- Author
-
Wollina, Uwe, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
13. Seborrheic Keratosis
- Author
-
Gündüz, Emin, Türsen, Ümit, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
14. Sarcoidosis
- Author
-
Quist, Sven, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
15. Purpuras
- Author
-
Lotti, Torello M., Tripo, Lara, Garzitto, Alice, Pietrzak, Aldona, Ghersetich, Ilaria, Farabi, Banu, Goldust, Mohamad, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
16. Pityriasis Rosea
- Author
-
Nikolić, Miloš, Lalošević, Jovan, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
17. Morphea (Localized Scleroderma)
- Author
-
Parodi, Aurora, Russo, Roberto, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
18. Pemphigus Foliaceus and Pemphigus Erythematosus
- Author
-
Hammers, Christoph M., Schmidt, Enno, Borradori, Luca, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
19. Mastocytosis
- Author
-
Van Gysel, Dirk, De Maeseneer, Hannelore, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
20. Lupus Erythematosus
- Author
-
Kuhn, Annegret, Landmann, Aysche, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
21. HIV Infection and AIDS: The Present Status of Antiretroviral Therapy
- Author
-
Paparizos, Vassilios, Kourkounti, Sofia, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
22. Adamantiades-Behçet Disease
- Author
-
Zouboulis, Christos C., Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
23. Urticaria
- Author
-
Lawlor, Frances, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
24. Grover Disease
- Author
-
Turk, Bengu Gerceker, Alper, Sibel, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
25. Cutaneous Vasculitis
- Author
-
Gianfaldoni, Serena, D’Erme, Angelo Massimiliano, Hercogova, Jana, Lotti, Torello M., Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
26. Chronic Actinic Dermatitis
- Author
-
O’Connor, Cathal, Murphy, Gillian M., Gulmann, Christian, O’Shea, Sally Jane, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
27. Vitiligo
- Author
-
Nicolaidou, Electra, Katsambas, Andreas D., Lotti, Torello M., Sharma, Aseem, Ganjoo, Shikhar, Mhatre, Madhulika, Goldust, Mohamad, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor
- Published
- 2023
- Full Text
- View/download PDF
28. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023.
- Author
-
Stratigos, Alexander J., Garbe, Claus, Dessinioti, Clio, Lebbe, Celeste, van Akkooi, Alexander, Bataille, Veronique, Bastholt, Lars, Dreno, Brigitte, Dummer, Reinhard, Fargnoli, Maria Concetta, Forsea, Ana Maria, Harwood, Catherine A., Hauschild, Axel, Hoeller, Christoph, Kandolf-Sekulovic, Lidija, Kaufmann, Roland, Kelleners-Smeets, Nicole WJ, Lallas, Aimilios, Leiter, Ulrike, and Malvehy, Josep
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *CONSENSUS (Social sciences) , *FRAIL elderly , *IMMUNOCOMPROMISED patients , *EPIDERMAL growth factor receptors , *DISEASES , *SKIN tumors , *TREATMENT effectiveness , *CANCER patients , *RISK assessment , *INTERPROFESSIONAL relations , *QUALITY of life , *HEALTH care teams , *DECISION making , *DESCRIPTIVE statistics , *RADIOTHERAPY , *SQUAMOUS cell carcinoma , *LONGITUDINAL method - Abstract
In order to update recommendations on treatment, supportive care, education, and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV), and the European Organisation of Research and Treatment of Cancer (EORTC) was formed. Recommendations were based on an evidence-based literature review, guidelines, and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable), and distant metastatic cSCC. For common primary cSCC, the first-line treatment is surgical excision with postoperative margin assessment or micrographically controlled surgery. Achieving clear surgical margins is the most important treatment consideration for patients with cSCCs amenable to surgery. Regarding adjuvant radiotherapy for patients with high-risk localised cSCC with clear surgical margins, current evidence has not shown significant benefit for those with at least one high-risk factor. Radiotherapy should be considered as the primary treatment for non-surgical candidates/tumours. For cSCC with cytologically or histologically confirmed regional nodal metastasis, lymph node dissection is recommended. For patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiotherapy, anti-PD-1 agents are the first-line systemic treatment, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drugs Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC, include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiotherapy. Multidisciplinary board decisions are mandatory for all patients with advanced cSCC, considering the risks of toxicity, the age and frailty of patients, and co-morbidities, including immunosuppression. Patients should be engaged in informed, shared decision-making on management and be provided with the best supportive care to improve symptom management and quality of life. The frequency of follow-up visits and investigations for subsequent new cSCC depends on underlying risk characteristics. • Treatment depends on the characteristics of the patient, e.g. frailty, co-morbidities, preferences, and of cSCC, e.g. primary low-risk or high-risk, locally advanced, regional metastatic (operable or inoperable), or distant metastatic. • Achieving clear surgical margins is the most important treatment consideration for patients with cSCC amenable to surgery. • Multidisciplinary board decisions are mandatory for all patients with advanced cSCC. • Anti-PD-1 agents (cemiplimab) are the first-line systemic treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Beta-Blockers for Hemangiomas
- Author
-
Gelmetti, Carlo, Cavalli, Riccardo, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
30. Antiviral Drugs
- Author
-
Skerlev, Mihael, Čulav-Košćak, Ivana, Basarovski, Jane, Stanimirović, Andrija, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
31. Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS)
- Author
-
Obeid, Grace, Valeyrie-Allanore, Laurence, Wolkenstein, Pierre, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
32. Pityriasis Rubra Pilaris
- Author
-
Petrov, Andrej, Pljakoska, Vesna, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
33. Pityriasis Rosea
- Author
-
Nikolic, Milos, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
34. Pemphigus Foliaceus and Pemphigus Erythematosus
- Author
-
Hammers, Christoph M., Schmidt, Enno, Borradori, Luca, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
35. Morphea (Localized Scleroderma)
- Author
-
Parodi, Aurora, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
36. Lupus Erythematosus
- Author
-
Kuhn, Annegret, Landmann, Aysche, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
37. HIV Infection and AIDS: Antiretroviral Therapy
- Author
-
Paparizos, Vassilios, Kourkounti, Sofia, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
38. Grover Disease
- Author
-
Turk, Bengu Gerceker, Alper, Sibel, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
39. Chronic Actinic Dermatitis
- Author
-
O’Shea, Sally Jane, Gulmann, Christian, Murphy, Gillian M., Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
40. Vitiligo
- Author
-
Nicolaidou, Electra, Katsambas, Andreas D., Lotti, Torello M., Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.